Boron-based prodrug strategies for increased bioavailability and lower required doses for drug molecules containing at least one phenol (or aromatic hydroxyl) group

摘要

Boron-based prodrugs of therapeutic molecules containing phenol or aromatic hydroxyl groups ("progenitor drugs"), their use, and methods of making them are provided, for example, improved bioavailability To achieve therapeutically effective dosages that are significantly reduced to reduce adverse effects while maintaining the desired therapeutic effect of the starting drug, and in particular long-term residence (eg, in the circulatory system) belongs to.